This is particularly crucial for the survival chances of those affected, as Staphylococcus aureus strains can be insensitive to various antibiotics. "If the bacteria in a blood sample first have to be cultivated for a diagnostic procedure, valuable time is lost," explains Qun Ren, the group leader from Empa's Biointerfaces lab in St. Gallen. Qun Ren and her team colleague Fei Pan therefore looked together with researchers from ETH Zurich for a way to bypass the lengthy intermediate step.
The team has developed a method using magnetic nanoparticles that can bind to staphylococci. The bacteria can thus be specifically detected via a magnetic field. In a next step, the sensitivity to antibiotics is analyzed using a chemiluminescence method. If resistant bacteria are in the test tube, the sample emits light. If, on the other hand, the germs can be killed with antibiotics, the reaction vessel remains dark. "All in all, the sepsis test takes around three hours – compared to several days for a classic cultivation of bacterial cultures," says Fei Pan.
Another unpleasant representative from the bacterial kingdom is Pseudomonas aeruginosa. This rod-shaped bacterium can cause various diseases, including infections of the urinary tract, for example, via a urinary catheter during a hospital stay. Such infections can subsequently develop into sepsis. And these pathogens are also often resistant to a number of antibiotics.
This is where another advantage of the magnetic nanoparticles comes into play: The method can be tailored to many different types of bacteria, similar to a modular system. In this way, Empa researchers were able to develop a rapid "sepsis sensor" based on magnetic nanoparticles. In samples containing artificial urine, the method reliably identified the bacterial species and determined possible resistance to antibiotics via a chemiluminescence reaction.
So far, the researchers have evaluated their magnetic nanoparticle kit for sepsis and urinary tract infections using laboratory samples. "In a next step, we would like to validate the sepsis tests together with our clinical partners by evaluating patient samples," says Qun Ren.
MEDICA-tradefair.com; Source: EMPA
